➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Moodys
Dow
Merck
Colorcon

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,772,897

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,772,897 protect, and when does it expire?

Patent 10,772,897 protects ELLA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-four countries.

Summary for Patent: 10,772,897
Title:Method for on-demand contraception
Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Inventor(s): Ulmann; Andre (Paris, FR), Gainer; Erin (Chardonne, CH), Mathe; Henri Camille (Paris, FR), Blithe; Diana (Silver Spring, MD), Nieman; Lynnette (Bethesda, MD)
Assignee: Laboratoire HRA-Pharma (Paris, FR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Bethesda, MD)
Application Number:16/230,802
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 10,772,897

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes   Start Trial   Start Trial A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,772,897

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010237120   Start Trial
Brazil PI1014035   Start Trial
Canada 2757496   Start Trial
China 102395373   Start Trial
Cyprus 1118236   Start Trial
Denmark 2419108   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Colorcon
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.